Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05929703 · ClinicalTrials.gov registry record · NA

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

A NA study of Alzheimer Disease and Aging, sponsored by University of Michigan.

Recruiting
Registry status
NA
Development phase
3,000
Enrollment target
7
Study locations

NCT05929703: Recruiting NA study of Alzheimer Disease and Aging, sponsored by University of Michigan.

NCT05929703 is a NA study of Alzheimer Disease and Aging that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 3,000 participants, roughly in line with the 2,741-participant average among 306 other Alzheimer Disease trials with a reported enrollment target. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05929703, a NA study of Alzheimer Disease and Aging, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
NA
Development phase
3,000 participants
Enrollment target
7
Study locations

Study Summary

The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes. 3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.

Primary Outcome

Any positive delirium screen (yes/no) as determined by the long-form Confusion Assessment Method (CAM), supplemented by a validated chart review approach for delirium.

Conditions Studied

Alzheimer Disease Aging Mild Cognitive Impairment Delirium Caregiver Burden Patient Satisfaction Implementation Science Family Members Neurocognitive Disorders Family Support

Interventions

  • BEHAVIORAL HELP
  • BEHAVIORAL FAM-HELP

Study Locations (7)

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • Allegheny General Hospital - Pittsburgh

California

  • Saddleback Medical Center - Orange

Maine

  • MaineHealth - Portland

Michigan

  • Michigan Medicine - Ann Arbor

Utah

  • University of Utah - Salt Lake City

Wisconsin

  • Meriter Hospital - Madison

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2023-12-04
Est. Completion 2027-08
Phase NA
University of Michigan

1,327 total trials

What NCT05929703 shows while recruiting

NCT05929703 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,741-participant average among 306 other Alzheimer Disease trials with a reported enrollment target.

The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which HELP is the first listed.

NCT05929703 lists 7 locations in 6 states (Pennsylvania, California, Maine).

Frequently Asked Questions

What is clinical trial NCT05929703 about?

NCT05929703 is a clinical study titled "Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders". The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are th...

What is the current status of trial NCT05929703?

This trial is currently recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2023-12-04. Estimated completion is 2027-08.

What conditions does trial NCT05929703 study?

This clinical trial studies the following conditions: Alzheimer Disease, Aging, Mild Cognitive Impairment, Delirium, Caregiver Burden.

What interventions are being tested in trial NCT05929703?

The interventions under investigation include: HELP (BEHAVIORAL), FAM-HELP (BEHAVIORAL).

Who is sponsoring clinical trial NCT05929703?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05929703 being conducted?

This trial has 7 study locations across California, Maine, Michigan, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05929703's enrollment target sits among peer trials

3,000 18th of 306 higher than 289 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05929703

Source: ClinicalTrials.gov NCT05929703, the US trial registry maintained by the National Library of Medicine. NCT05929703 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.